NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Characteristics and Outcomes of Patients Who Received Etravirine and/or Darunavir

NCT04194021

CompletedN/A

Sponsor: Elizabeth Glaser Pediatric AIDS Foundation

Conditions: HIV/AIDS

Countries: Cameroon, Eswatini, Kenya, Lesotho, Uganda

The objectives of this data collection activity are to: 1. Describe the baseline demographics, clinical and laboratory profile of patients who ever received darunavir (DRV) and/or etravirine (ETR), at the time of initiation on DRV and/or ETR; 2. Describe the clinical and laboratory profile of patients who ever received DRV and/or ETR every 6 months from the first data collection point through 2021; 3. Describe dynamics in HIV drug resistance mutations among patients who fail treatment on new regimens including DRV and/or ETR; 4. Describe demographics, clinical and laboratory profile of young adults who transition out of the donation program after the age of 25 years at 12 months after their transition.

Eligibility overview

Sex: ALL

Age: — to 25 Years

Healthy volunteers: Yes

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Ever received darunavir and/or etravirine.
* Under age 25.
* Residing in any of the following countries: Cameroon, Ethiopia, Eswatini, Kenya, Lesotho, Nigeria, Rwanda, Uganda, Zambia, and Zimbabwe.

Exclusion Criteria:

* Above age 25.
* Residing in a country not participating in the New Horizons Collaborative.

Locations (5)

Yaoundé, Centre Region, Cameroon
Mbabane, Hhohho Region, Eswatini
Nairobi, Kenya
Maseru, Lesotho
Mbarara, Uganda